10124420Bio-Hermes 2: Cambridge Cognition Digital BiomarkersActiveCollaborative R&DInnovate UKA large, international research project called Bio-Hermes 2 aims to study Alzheimer's Disease by collecting data on digital and blood biomarkers (signs that can indicate if someone has the disease). The project wants to see how well these biomarkers match up with existing tests, such as PET scans, which show what's happening in the brain. Cambridge Cognition, a UK-based company, is contributing to this project by providing tools to measure digital biomarkers through touch screen and voice assessments on an iPad. These tests look at memory, language, and other cognitive skills that are affected early on in Alzheimer's. Cambridge Cognition has extensive experience working with clinical trials and has supported over 3,000 studies. They follow strict industry standards to ensure the project is done efficiently and accurately. The results of this project will help us to develop tools which can help to identify the earliest signs of Alzheimer's Disease. These tools can be used to help screen for early Alzheimer's Disease for both clinical trials and in healthcare settings, which is becoming more important now that there are treatments being developed which target specific early brain changes found in this devastating disease. Overall, the Bio-Hermes 2 project aims to advance our understanding of Alzheimer's by collecting new types of data and seeing how they match up with existing tests. The results will have a significant impact on Cambridge Cognition and potentially lead to better diagnosis and treatment of the disease.